Health Care
Commentary
Congress Must Prioritize Patients, Not Insurers, In Renewed Healthcare Debate
Congress has returned to Washington. Democrats are renewing their call to extend COVID-era health insurance subsidies to shield people from hefty premium increases. Just last week, some Republicans in the House joined them to pass a bill that extends these subsidies—putting the question squarely before the Senate. That approach would ...
Sally C. Pipes
January 13, 2026
Commentary
California should embrace competition to promote better health insurance
Following a depressingly familiar pattern, California is once again undermining health care competition in the vain hope that less competition will lead to lower prices. It won’t. In its latest anti-competitive actions, starting Jan. 1, California’s Department of Health Care Services will be limiting competition for plans (called Medi-Medi plans) ...
Wayne H Winegarden
December 31, 2025
Blog
How can we make drugs more affordable without sacrificing future cures?
How can we make drugs more affordable without sacrificing future cures? To a large extent, the current system works fairly well already to make most of the drugs that Americans take affordable. And that’s because of our robust generics market. Around 90% of prescriptions filled each year are for generics ...
Sally C. Pipes
December 31, 2025
Commentary
Medicare for All remains a disaster proposition
Medicare for All is poised for a comeback. Earlier this month, Rep. Pramila Jayapal (D-WA), the former head of the Congressional Progressive Caucus, released polling data showing strong support for the idea among Democrats. Jayapal’s renewed push for socialized medicine comes as many Democratic candidates for U.S. Senate are putting ...
Sally C. Pipes
December 29, 2025
Commentary
Terrible Effects of Medicare Price Controls Are Here
Medicare will impose price controls on prescription drugs for the first time when the calendar flips to January. Even before those controls formally take effect, the damage is already being done. The scheme has begun to hollow out America’s biomedical research ecosystem. Patients will pay the price — in the ...
Sally C. Pipes
December 26, 2025
Commentary
What America Needs from a GOP Healthcare Package
The U.S. House just passed legislation that will help make health insurance more affordable — without extending the enhanced premium subsidies for exchange coverage that Democrats enacted during the COVID-19 pandemic. The House action comes on the heels of votes on two measures in the Senate: one from Democrats that ...
Sally C. Pipes
December 24, 2025
Blog
Do price controls affect which drugs patients have access to and how soon?
Do price controls affect which drugs patients have access to and how soon? They absolutely do. Just look at the situation in Europe. For years, drug companies have been choosing to withhold certain medicines from European markets rather than accept the price constraints imposed by governments there. As a result, ...
Sally C. Pipes
December 24, 2025
Health Care
New PRI Brief: Patent Taxes Threaten America’s Most Productive Engine of Growth
SACRAMENTO. (December 22, 2025) — The free-market Pacific Research Institute today released an issue brief finding that the Trump administration’s proposed 50% tax on patent revenue from inventions created using federal grants would disincentivize universities from expending the time, money, and effort to engage in federally-funded research. “Universities respond to ...
Sally C. Pipes
December 22, 2025
Blog
How do price controls damage innovation?
What role do intellectual property laws play in encouraging innovation? They are absolutely essential. IP protections like patents reward those who succeed in creating new medicines and ushering them through the regulatory approval process. They do this by guaranteeing that the IP rights holder behind a new drug will have ...
Sally C. Pipes
December 17, 2025
Commentary
Chaos At The FDA Benefits America’s Rivals—At The Expense Of America’s Patients
Chaos has become the norm at the U.S. Food and Drug Administration. And it’s putting American patients, not to mention our country’s world-leading life sciences sector, at risk. Earlier this year, roughly 3,500 FDA employees were laid off. The agency’s Center for Drug Evaluation and Research, which oversees prescription and ...
Sally C. Pipes
December 15, 2025
Congress Must Prioritize Patients, Not Insurers, In Renewed Healthcare Debate
Congress has returned to Washington. Democrats are renewing their call to extend COVID-era health insurance subsidies to shield people from hefty premium increases. Just last week, some Republicans in the House joined them to pass a bill that extends these subsidies—putting the question squarely before the Senate. That approach would ...
California should embrace competition to promote better health insurance
Following a depressingly familiar pattern, California is once again undermining health care competition in the vain hope that less competition will lead to lower prices. It won’t. In its latest anti-competitive actions, starting Jan. 1, California’s Department of Health Care Services will be limiting competition for plans (called Medi-Medi plans) ...
How can we make drugs more affordable without sacrificing future cures?
How can we make drugs more affordable without sacrificing future cures? To a large extent, the current system works fairly well already to make most of the drugs that Americans take affordable. And that’s because of our robust generics market. Around 90% of prescriptions filled each year are for generics ...
Medicare for All remains a disaster proposition
Medicare for All is poised for a comeback. Earlier this month, Rep. Pramila Jayapal (D-WA), the former head of the Congressional Progressive Caucus, released polling data showing strong support for the idea among Democrats. Jayapal’s renewed push for socialized medicine comes as many Democratic candidates for U.S. Senate are putting ...
Terrible Effects of Medicare Price Controls Are Here
Medicare will impose price controls on prescription drugs for the first time when the calendar flips to January. Even before those controls formally take effect, the damage is already being done. The scheme has begun to hollow out America’s biomedical research ecosystem. Patients will pay the price — in the ...
What America Needs from a GOP Healthcare Package
The U.S. House just passed legislation that will help make health insurance more affordable — without extending the enhanced premium subsidies for exchange coverage that Democrats enacted during the COVID-19 pandemic. The House action comes on the heels of votes on two measures in the Senate: one from Democrats that ...
Do price controls affect which drugs patients have access to and how soon?
Do price controls affect which drugs patients have access to and how soon? They absolutely do. Just look at the situation in Europe. For years, drug companies have been choosing to withhold certain medicines from European markets rather than accept the price constraints imposed by governments there. As a result, ...
New PRI Brief: Patent Taxes Threaten America’s Most Productive Engine of Growth
SACRAMENTO. (December 22, 2025) — The free-market Pacific Research Institute today released an issue brief finding that the Trump administration’s proposed 50% tax on patent revenue from inventions created using federal grants would disincentivize universities from expending the time, money, and effort to engage in federally-funded research. “Universities respond to ...
How do price controls damage innovation?
What role do intellectual property laws play in encouraging innovation? They are absolutely essential. IP protections like patents reward those who succeed in creating new medicines and ushering them through the regulatory approval process. They do this by guaranteeing that the IP rights holder behind a new drug will have ...
Chaos At The FDA Benefits America’s Rivals—At The Expense Of America’s Patients
Chaos has become the norm at the U.S. Food and Drug Administration. And it’s putting American patients, not to mention our country’s world-leading life sciences sector, at risk. Earlier this year, roughly 3,500 FDA employees were laid off. The agency’s Center for Drug Evaluation and Research, which oversees prescription and ...
